(158) Lipid Polymer Hybrid Nanoparticles for pulmonary mRNA delivery
Introduction: The pulmonary delivery of mRNA represents a groundbreaking opportunity to treat diseases as cystic fibrosis or to achieve mucosal vaccination. However, conventional lipid nanoparticle formulations lack the necessary stability to withstand the shear stress during nebulization (1, 2). Beyond sufficient robustness, nanocarriers must also overcome extracellular barriers as mucus and facilitate the endosomal escape of mRNA (3). We address these challenges by utilizing Lipid Polymer Hybrids (LPHs) that combine the favorable stability of polymers with the superior transfection efficiency of lipids.
Learning Objectives:
identify the key challenges associated with mRNA delivery to the lungs via inhalation.
understand how excipients can help to overcome technological and biological barriers.
explain the design of core-shell structured hybrid nanoparticles including lipids and polymers.
